Anti–TROP-2 antibody–drug conjugate delivering SN-38 (topoisomerase I inhibitor) to TROP-2–positive tumor cells.
Humanized anti–TROP-2 monoclonal antibody (hRS7) delivers the topoisomerase I inhibitor payload SN-38 to TROP-2–expressing tumor cells. After binding and internalization, linker cleavage releases SN-38, which stabilizes topoisomerase I–DNA complexes, causing DNA breaks, replication arrest, and apoptosis.
NO
INDIRECT
The ADC targets TROP-2 on tumor cells; after internalization it releases SN-38, which inhibits topoisomerase I to cause DNA damage and apoptosis. Topoisomerase I is the intracellular payload target, not the binding antigen, so its expression alone does not make cells targeted for killing.
Humanized IgG1 monoclonal antibody against HER2 (ERBB2) that binds the extracellular domain of HER2 on tumor cells, inhibits HER2-driven signaling and receptor shedding, and engages immune effector cells via Fc-gamma receptors to trigger antibody-dependent cellular cytotoxicity (ADCC) against HER2-overexpressing tumor cells.
YES
DIRECT
Trastuzumab binds HER2 on tumor cells and engages Fc-gamma receptors (e.g., CD16) on NK cells/macrophages to trigger antibody-dependent cellular cytotoxicity and phagocytosis, killing HER2-expressing cells.
Humanized monoclonal antibody targeting the HER2 (ERBB2) extracellular dimerization domain (domain II); blocks HER2 heterodimerization (e.g., with HER3), inhibiting downstream signaling (PI3K/AKT, MAPK) and inducing tumor cell death, while also mediating Fc-dependent ADCC.
YES
DIRECT
IgG1 antibody binds HER2 and engages Fcγ receptors on immune effectors (e.g., NK cells) to mediate ADCC/ADCP, killing HER2+ cells; blockade of HER2 dimerization also promotes apoptosis via signaling inhibition.
Proposed daratumumab biosimilar by Biocad; a fully human IgG1κ monoclonal antibody targeting CD38 that induces CDC, ADCC, ADCP, apoptosis, and modulates CD38 NADase activity.
BCD-264 is a daratumumab biosimilar, a fully human IgG1κ monoclonal antibody targeting CD38. It depletes CD38-expressing cells via complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP), can induce apoptosis upon cross-linking, and modulates/inhibits CD38 NADase enzymatic activity.
YES
DIRECT
Anti-CD38 IgG1 binds CD38 on target cells and eliminates them via complement-dependent cytotoxicity, Fc-mediated ADCC by NK/effector cells, antibody-dependent phagocytosis, and apoptosis upon cross-linking.
Daratumumab; a fully human IgG1κ monoclonal antibody against CD38 that mediates CDC, ADCC, ADCP, induces apoptosis, and modulates CD38 NADase activity.
Daratumumab is a fully human IgG1κ monoclonal antibody targeting CD38 on plasma cells; it depletes CD38+ cells via complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP), can induce apoptosis upon crosslinking, and modulates CD38 ectoenzyme (NADase) activity, disrupting CD38/NAD+ signaling.
YES
DIRECT
Daratumumab binds CD38 on target cells and triggers complement-dependent lysis (CDC), FcγR-mediated ADCC and ADCP by immune effector cells, and can induce apoptosis upon crosslinking.